NGNE - NASDAQ

Neurogene Inc.

NGNE·NASDAQ

$27.53

+5.3%

HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$435.04M

EPS-4.2400

P/E Ratio-6.49

Earnings Date08/07/2026

ngne

Net Cash Provided by Financing Activities

Last Annual Value

30.43M

3-Year CAGR

-23%

5-Year CAGR

-17%

10-Year CAGR

-11%

Adjust for Inflation

Neurogene Inc. Competitors Analysis of Net Cash Provided by Financing Activities

NGNE · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Neurogene Inc. NASDAQ:NGNE	30.43M	-31.0%	-9.8%	-8.1%
Ocugen, Inc. NASDAQ:OCGN	17.33M	-6.0%	-32.2%	-4.4%
Alumis Inc. Common Stock NASDAQ:ALMS	2.07M	-71.5%	N/A	N/A
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT	148.00K	-91.1%	-67.0%	149.2%
4D Molecular Therapeutics, Inc. NASDAQ:FDMT	112.96M	-10.4%	-0.9%	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	101.45M	-20.5%	3.9%	13.4%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	189.59M	39.9%	N/A	N/A
Benitec Biopharma Inc. NASDAQ:BNTC	70.48M	63.9%	25.6%	14.9%
Lineage Cell Therapeutics, Inc. AMEX:LCTX	26.95M	61.3%	-6.1%	-1.9%
PureTech Health plc NASDAQ:PRTC	-6.34M	N/A	N/A	N/A
Fulcrum Therapeutics, Inc. NASDAQ:FULC	168.67M	12.6%	-2.0%	N/A

Neurogene Inc. Fair Value Envelope

NGNE · NASDAQ

Our analysis suggests that NGNE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.531, this represents a potential HIDDEN relative to our calculated worth for Neurogene Inc..

HIDDEN

Intrinsic Value

Current Price: $27.531

Related Guides

Blog Categories

Continue your NGNE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.